3Campbell L, Shin, EC, Shin WC et al, 1999. Effect of interferongamma on the susceptibility to Fas( CD95/APO - 1 ) - mediated cell death in human hepatoma cells. Brain Research ,835 (1):46-61
4Qi s, Lu Y, Pan J, et al. Anatomic relations of the arach- noidea around the pituitary stalk: relevance for surgical removal of craniopharyngiomas [J]. Acta Neurochir, 2011, 153(4): 785-796.
5Leng LZ, Greenfield JP, Souweidane MM, et al. Endo- scopic, endonasal resection ofcraniopharyngiomas: analysis of outcome including extent of resection, cerebrospinal fluid leak, return to preoperative productivity, and body mass index [J]. Neurosurgery, 2012, 70(1): 110-124.
6Yang I, Sughrue ME, Rutkowski MJ, et al. Craniopharyn- gioma: a comparison of tumor control with various treat- ment strategies [J]. Neurosurg Focus, 2010, 28(4): E5.
7Schwartz TH, Anand VK. The endoscopic endonasal transsphenoidal approach to the suprasellar cistern [J]. Clin Neurosurg, 2007, 54: 26-35.
8KassamAB, GardnerPA, SnydermanCH, et al. Expanded endonasal approach, a fully endoscopic transnasal approach for the resection of midline suprasellar craniopharyn- giomas: a new classification based on the infundibulum [J]. J Neurosurg, 2008, 108(4): 715-728.
9Cavalheiro S, Di Rocco C, Valenzuela S, et al. Cranio- pharyngiomas: intratumoral chemotherapy with interferon- alpha: a multieenter preliminary study with 60 cases [J]. Neurosurg Focus, 2010, 28(4): E12.
10Xu Z, Yen CP, Schlesinger D, et al. Outcomes of Gamma Knife surgery for craniopharyngiomas [J]. J Neurooneol, 2011, 104(1): 305-313.
